NYSE:ELANPharmaceuticals
Elanco Animal Health (ELAN) Is Up 5.7% After Beating Q4 Views And Raising 2026 Innovation Outlook
Elanco Animal Health reported past fourth-quarter 2025 sales of US$1,144 million and full-year 2025 sales of US$4.72 billion, but moved from prior net income to a net loss of US$276 million for the quarter and US$232 million for the year.
At the same time, Elanco exceeded revenue and adjusted earnings expectations, raised its 2026 innovation revenue outlook, announced the AHV International acquisition, and received USDA approval for Befrena, underscoring how product launches and portfolio...